BTIG Keeps a Buy Rating on Avita Medical (RCEL)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Avita Medical (RCELResearch Report) on July 19 and set a price target of $37.00. The company’s shares closed last Thursday at $19.77.

According to, Zimmerman is a 5-star analyst with an average return of 29.0% and a 61.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Staar Surgical Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avita Medical with a $32.33 average price target.

See today’s analyst top recommended stocks >>

Avita Medical’s market cap is currently $492.6M and has a P/E ratio of -12.10. The company has a Price to Book ratio of 4.07.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCEL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.